×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Dishman Pharma sees Rs 100 cr debt reduction in FY16
Margins to pick up in H2, will meet FY15 guidance: Dishman
Dishman pins hopes on China unit
Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx
Pharma cos likely to post 21% EBITDA growth in Q4: MOST
See pharma sector's Q3 topline to grow 22%: Motilal Oswal
See pharma sector's margins to dip 314 bps in 3QFY13: Angel
Contract research to boost performance in FY13: Dishman
Dishman Pharma expects 25% growth in FY13
See strong performance by pharma in Mar quarter: KR Choksey
Better R&D income led to jump in profits: Dishman Pharma
Pharma Q3: New launches, generic drug demand to aid growth
Pharma stocks results preview for Q3FY12: KRChoksey
Pharmaceutical results preview for Q3FY12: Emkay
Dishman Pharma eyes over 15% topline growth going forward
Dishman Sept qtr PAT seen down 50% at Rs 15 cr: KR Choksey
Dishman Sept qtr PAT seen up 21% at Rs 10cr: Dolat Capital
Dishman Pharma Mar qtr PAT seen down at Rs 2.3 cr: MOST
Dishman Pharma March qtr PAT seen at Rs 3cr: KRChoksey
Q4 to be better compared to Q3: Dishman Pharma
Dishman Pharma Dec qtr PAT seen up 11% at Rs 36.7cr: Angel
Dishman Pharma Dec qtr PAT seen down 47% at Rs 17cr: Karvy
Dishman Pharma Dec qtr PAT seen up 3% at Rs 34cr: KRChoksey
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio